Keyphrases
Epigenetic Reprogramming
100%
NUT Midline Carcinoma
100%
Histone Deacetylase Inhibitor (HDACi)
66%
Bromodomain-containing Protein 4 (BRD4)
50%
Squamous Differentiation
33%
Potential Therapeutics
16%
Growth Inhibition
16%
Positron Emission Tomography
16%
Small Interfering RNA (siRNA)
16%
Transcriptional Repression
16%
FDA-approved Drugs
16%
Survival Benefit
16%
Fusion Protein
16%
Attenuation
16%
Therapeutic Utility
16%
Translational Studies
16%
Histone Acetylation
16%
Loss of Expression
16%
Xenograft Model
16%
Objective Response
16%
Expression Assay
16%
Carcinoma Cells
16%
Primary Tumor Cells
16%
Growth in Vitro
16%
Differentiation Therapy
16%
Vorinostat
16%
Pediatric Tumors
16%
Chromatin Acetylation
16%
Biochemistry, Genetics and Molecular Biology
BRD4
100%
Reprogramming
100%
Histone Deacetylase
100%
Small Interfering RNA
33%
Acetylation
33%
Histone Acetylation
33%
Growth Inhibition
33%
Positron Emission Tomography
33%
Chimeric Protein
33%
Medicine and Dentistry
NUT Midline Carcinoma
100%
Histone Deacetylase Inhibitor
66%
Primary Tumor
16%
Carcinoma Cell
16%
In Vitro
16%
Xenograft
16%
Tumor Cell
16%
Growth Inhibition
16%
Positron Emission Tomography
16%
Small Interfering RNA
16%
Histone Acetylation
16%
Differentiation Therapy
16%
Vorinostat
16%
Chimeric Protein
16%
Pediatric Cancer
16%
Acetylation
16%
Immunology and Microbiology
Histone
100%
Xenograft
33%
Tumor Cell
33%
Carcinoma Cell
33%
Histone Acetylation
33%
Acetylation
33%
Growth Inhibition
33%
Positron Emission Tomography
33%
Pharmacology, Toxicology and Pharmaceutical Science
Carcinoma
100%
Histone Deacetylase Inhibitor
66%
Small Interfering RNA
16%
Histone
16%
Chimeric Protein
16%
Vorinostat
16%
Neoplasm
16%
Primary Tumor
16%